vTv Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

vTv Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-113.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-113.5%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Aug 17

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Mar 03

vTv Therapeutics inks licensing deal for HPP971, shares up 11%

Dec 15

MacAndrews & Forbes buys 625K shares of vTv Therapeutics

Dec 11

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: VTVT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: VTVT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

vTv Therapeutics Piyasaya Karşı Temettü Getirisi

VTVT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (VTVT)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (VTVT) (3 yıla kadar)	n/a

Önemli Temettü: VTVT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, VTVT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: VTVT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: VTVT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

vTv Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

New major risk - Share price stability

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

New minor risk - Shareholder dilution

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

vTv Therapeutics Inc., Annual General Meeting, Jun 11, 2024

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

New minor risk - Shareholder dilution

Less than half of directors are independent

vTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Board Changes

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4.923802 million.

Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors

vTv Therapeutics Receives Non-Compliance Notice From Nasdaq

Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer

New minor risk - Share price stability

New major risk - Negative shareholders equity

First half 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1H 2022)

Nasdaq Approves vTv Therapeutics' Request to Extend the Period to Regain Compliance with the Minimum Bid Requirement Until December 18, 2023

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.10 loss in 1Q 2022)

vTv Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations

vTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel

vTv Therapeutics Receives a Letter from NASDAQ Regarding Minimum Bid Price

vTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer

Independent Director recently bought US$51k worth of stock

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021)

High number of new directors

Consensus revenue estimates increase by 17%

vTv Therapeutics Inc. Appoints Jonathan Isaacsohn as Member and Chair of the Board

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.01 loss in 2Q 2021)

vTv Therapeutics GAAP EPS of -$0.04

High number of new directors

vTv Therapeutics Inc. Announces CEO Changes

Jon Isaacsohn to Join the vTv Therapeutics Inc. Board of Directors

vTv stock soars 18% on $10M equity investment by CinRx Pharma

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics Inc. announced that it expects to receive $24.999762 million in funding from G42 Investments Ai Holding Rsc Ltd

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.075 loss in 1Q 2021)

vTv Therapeutics Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$5.00

Robin E. Abrams Resigns as Executive Chairperson of the Board of Directors of vTv Therapeutics Inc

vTv Therapeutics Inc. Announces Not to Stand for Re-Election of Noel Spiegel as Director and Chair of the Audit Committee of the Board

Price target decreased to US$5.00

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Inc. Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

vTv Therapeutics Inc.(NasdaqCM:VTVT) dropped from Russell 3000E Index

First quarter 2021 earnings released: US$0.075 loss per share (vs US$0.11 loss in 1Q 2020)

vTv Therapeutics Inc. Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

Director recently bought US$172k worth of stock

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Full year 2020 earnings released: US$0.18 loss per share (vs US$0.59 loss in FY 2019)

Revenue beats expectations

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

vTv Therapeutics inks licensing deal for HPP971, shares up 11%

MacAndrews & Forbes buys 625K shares of vTv Therapeutics

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme